Literature DB >> 11344241

Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene.

H H Schmidt1, J Genschel, P Baier, M Schmidt, J Ockenga, U J Tietge, M Pröpsting, C Büttner, M P Manns, H Lochs, G Brabant.   

Abstract

Lipatrophic diabetes, also referred to as familial partial lipodystrophy, is a rare disease that is metabolically characterized by hypertriglyceridemia and insulin resistance. Affected patients typically present with regional loss of body fat and muscular hypertrophic appearance. Variable symptoms may comprise pancreatitis and/or eruptive xanthomas due to severe hypertriglyceridemia, acanthosis nigricans, polycystic ovaria, and carpal tunnel syndrome. Mutations within the LMNA gene on chromosome 1q21.2 were recently reported to result in the phenotype of familial partial lipodystrophy. The genetic trait is autosomal dominant. We identified a family with partial lipodystrophy carrying the R482W (Arg(482)Trp) missense mutation within LMNA. Here we present the lipoprotein characteristics in this family in detail. Clinically, the loss of sc fat and muscular hypertrophy especially of the lower extremities started as early as in childhood. Acanthosis and severe hypertriglyceridemia developed later in life, followed by diabetes. The characterization of the lipoprotein subfractions revealed that affected children present with hyperlipidemia. The presence and severity of hyperlipidemia seem to be influenced by age, apolipoprotein E genotype, and the coexistence of diabetes mellitus. In conclusion, dyslipemia is an early and prominent feature in the presented lipodystrophic family carrying the R482W mutation within LMNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344241     DOI: 10.1210/jcem.86.5.7500

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Diseases of the Nucleoskeleton.

Authors:  James M Holaska
Journal:  Compr Physiol       Date:  2016-09-15       Impact factor: 9.090

Review 2.  Genetics of Lipodystrophy.

Authors:  Marissa Lightbourne; Rebecca J Brown
Journal:  Endocrinol Metab Clin North Am       Date:  2017-02-22       Impact factor: 4.741

3.  New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.

Authors:  Angelika Lüdtke; Janine Buettner; Hartmut H-J Schmidt; Howard J Worman
Journal:  J Med Genet       Date:  2007-09       Impact factor: 6.318

Review 4.  RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.

Authors:  Jian Liu; Scott Q Harper
Journal:  Curr Gene Ther       Date:  2012-08       Impact factor: 4.391

5.  Body fat distribution in women with familial partial lipodystrophy caused by mutation in the lamin A/C gene.

Authors:  Luciana Z Monteiro; Maria C Foss-Freitas; Renan M Júnior Montenegro; Milton C Foss
Journal:  Indian J Endocrinol Metab       Date:  2012-01

6.  Nuclear Factor-Y is an adipogenic factor that regulates leptin gene expression.

Authors:  Yi-Hsueh Lu; Olof Stefan Dallner; Kivanc Birsoy; Gulya Fayzikhodjaeva; Jeffrey M Friedman
Journal:  Mol Metab       Date:  2015-02-13       Impact factor: 7.422

7.  Abnormal adipose tissue distribution with unfavorable metabolic profile in five children following hematopoietic stem cell transplantation: a new etiology for acquired partial lipodystrophy.

Authors:  Masanori Adachi; Yumi Asakura; Koji Muroya; Hiroaki Goto; Hisato Kigasawa
Journal:  Clin Pediatr Endocrinol       Date:  2013-10-26

Review 8.  Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review.

Authors:  Nidhi Gupta; Noor Asi; Wigdan Farah; Jehad Almasri; Patricia Barrionuevo; Mouaz Alsawas; Zhen Wang; Morey W Haymond; Rebecca J Brown; M Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

9.  Missense Variants in PAX4 Are Associated with Early-Onset Diabetes in Chinese.

Authors:  Aibo Gao; Bin Gu; Juan Zhang; Chen Fang; Junlei Su; Haorong Li; Rulai Han; Lei Ye; Weiqing Wang; Guang Ning; Jiqiu Wang; Weiqiong Gu
Journal:  Diabetes Ther       Date:  2020-11-20       Impact factor: 2.945

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.